Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients

Journal of Immunotherapy

Volumn 20, Issue 6, 1997, Pages 496-504

  Luiten, Rosalie M ^a   Warnaar, Sven O ^a   Sanborn, David ^b   Lamers, Cornelis H J ^c   Bolhuis, Reinder L H ^c   Litvinov, Sergey V ^a   Zurawski Jr , Vincent R ^b,d   Coney, Leslie R ^b,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b CENTOCOR INC   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Apollon Inc   (United States)

Author keywords

Folate binding protein; Human anti murine immunoglobulin antibodies; Monoclonal antibody

Indexed keywords

BINDING PROTEIN; CD3 ANTIGEN; CHROMIUM 51; FOLATE BINDING PROTEIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; MONOCLONAL ANTIBODY;

ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CHIMERA; CYTOLYSIS; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL;

EID: 0030773742     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199711000-00010     Document Type: Article

References (38)

1. Griffiths CT, Parker L. Cancer of the ovary. In: Knapp RC, Berkowitz RS. eds. Gynecologic oncology. 313th ed. New York: McGraw-Hill, 1994.
2. Liu MA, Kranz DM, Kurnick JT, Boyle LA, Levy R, Eisen HN. Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1985;82:8648-52.
3. Jung G, Honsik CJ, Reisfeld RA, Muller-Eberhard HJ. Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates. Proc Natl Acad Sci USA 1986;83:4479-83.
4. Perez P, Titus JA, Lotze MT, et al. Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J Immunol 1986;137:2069-72.
5. Fanger MW, Segal DM, Wunderlich JR. Going both ways; bispecific antibodies and targeted cellular cytotoxicity. Science 1990;4: 2846-9.
6. Fanger MW, Segal DM, Romet-Lemonne JL. Bispecific antibodies and targeted cellular cytotoxicity. Immunol Today 1991;12:51-4.
7. Miotti S, Canevari S, Menard S, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. In l J Cancer 1987; 39:297-303.
8. Campell IG, Jones TA, Foulkes WD, Trowsdale J. Folate binding protein is a marker for ovarian cancer. Cancer Res 1991;51:5329-38.
9. Coney LR, Tomassetti A, Carayannopoulos L, et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991;51:6125-32.
10. Vegglan R, Fasolato S, Menard S, et al. Immunohistochemical reactivity of a monoclonal antibody prepared against human ovarian carcinoma on normal and pathological female genital tissues. Tumori 1989;75:510-3.
11. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992;52:3396-401.
12. Weitman SD, Weinberg AG, Coney LR, Zurawski VR Jr, Jennings DS, Kamen BA. Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res 1992;52:6708-11.
13. Lanzavecchia A, Scheidegger D. The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 1987;17: 105-11.
14. Mezzanzanica D, Canevari S, Menard S, et al. Human ovarian carcinoma lysis by cytotoxic T cells targeted by bi-specific monoclonal antibodies: analysis of the antibody components. Int J Cancer 1988;41:609-15.
15. Canevari S, Menard S, Mezzanzanica D, et al. Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T-cells. Int J Cancer Suppl 1988;2:18-21.
16. van Ravenswaay Claasen HH, van de Griend RJ, Mezzanzanica D, Bolhuis RLH, Warnaar SO, Fleuren GJ. Analysis of production, purification, and cytolytic potential of bi-specific antibodies reactive with ovarian-carcinoma-associated antigens and the T-cell antigen CD3. Int J Cancer 1993;55:128-36.
17. 2 antibody prolong host survival in a murine xenograft model. Cancer Res 1991;51:5716-21.
18. Bolhuis RL, Lamers CH, Goey SH, et al. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer Suppl 1992;7:78-81.
19. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995;87:1463-9.
20. Lamers CHJ, Gratama JW, Warnaar SO, Stoter G, Bolhuis RLH. Inhibition of bispecific monoclonal antibody (BSAB)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with BSAB-targeted activated T lymphocytes. Int J Cancer 1995;60:450-7.
21. Schroff RW, Foo KH, Beatty SM, Oldham RK, Morgan AC. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985;45:879-85.
22. Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985;135:1530-35.
23. Courtnay-Luck NS, Epenetos AA, Moore R, et al. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 1986;46:6489-93.
24. Blottiere HM, Maurel C, Douillard JY. Immune function of patients with gastrointestinal carcinoma after treatment with multiple infusions of monoclonal antibody 17-1A. Cancer Res 1987;47: 5238-41.
25. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86:4220-4.
26. Benard J, Da Silva J, De Blois MC, et al. Characterization of a human ovarian adenocarcinoma line, IGROV-1, in tissue culture and in nude mice. Cancer Res 1985;45:4970-9.
27. Luiten RM, Coney LR, Fleuren GJ, Warnaar SO, Litvinov SV. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer 1996; 73:735-44.
28. Coney LR, Mezzanzanica D, Sanborn D, Casalini P, Colnaghi MI, Zurawski VR Jr. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res 1994;54:2448-55.
29. Sun LK, Curtis P, Rakowicz-Sculczynska E, Grayeb J, Daddona P, Koprowski H. Chimeric antibody with human constant regions and mouse variable regions directed against carcinoma-associated antigen 17-1A. Proc Natl Acad Sci USA 1987;84:214-18.
30. Looney JE, Knight DM, Moore-Arevalo M, et al. High level expression and characterization of a mouse-human chimeric CD4 antibody with therapeutic potential. Hum Antibodies Hybridomas 1992;3:191-200.
31. Miotti S, Mantovani L, Pupa SM, Bellosta P, Colnaghi MI. Characterization of two anti-idiotypic monoclonal antibodies raised against the anti-tumour monoclonal antibody MOv18. J Immunol Res 1989;1:59.
32. 2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer. Hybridoma 1994;13(6):519-25.
33. Velders MP, Litvinov SV, Warnaar SO, et al. New chimeric antipancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency. Cancer Res 1994;54:1753-9.
34. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979;76:1438.
35. De Sutter K, Fiers W. A bifunctional murine: human chimeric antibody with one antigen-binding arm replaced by bacterial β-lactamase. Mol Immunol 1994;31:261-7.
36. Bruynck A, Seemann G, Bosslet K. Characterisation of a humanised bispecific monoclonal antibody for cancer therapy. Br J Cancer 1993;67:436-40.
37. Tada H, Kurokawa T, Seita T, Watanabe T, Iwasa S. Expression and characterization of a chimeric bispecific antibody against fibrin and against urokinase-type plasminogen activator. J Biotechnol 1994;33:157-74.
38. Phelps JL, Beidler DE, Jue RA, Unger BW, Johnson MJ. Expression and characterization of a chimeric bifunctional antibody with therapeutic applications. J Immunol 1990;145(4):1200-4.